News
A Significant Step Toward Greater Clarity in Polymorph Control for Innovative Drugs
28 Jan 2026
en
Crystal Pharmatech is returning to DCAT Week with expanded capabilities. We have grown into a global CDMO with 300+ scientists across the US, Canada, and China, having supported over 2,000 NCEs to date. While we remain leaders in avoiding early-stage CMC pitfalls, we now offer true "Molecule to Medicine" support across three specialized platforms.
We invite you to discuss how our three specialized platforms can de-risk your 2026 development goals:
Small Molecules: From solid-state research and preformulation to GMP manufacturing (First-Time-Right approach).
Biologics (Crystal Bio Solutions): Bioanalytical testing, biomarker analysis, and CMC analytics.
Nucleic Acids (Crystal NAX): End-to-end solutions for nucleic acid therapeutics.
We are hosting private strategy sessions to help you navigate your upcoming CMC and development milestones.
Alex Chen, Ph.D.
Co-founder & CEO
Crystal Pharmatech
Robert Wenslow, Ph.D.
Co-founder and CBO
Crystal Pharmatech
Yongqiang Li, Ph.D.
CEO of Canada CDMO BU
Candoo Pharmatech
Derik McCathy
Subject Matter Expert
Crystal Pharmatech
Yan Li
Senior Director
Crystal Pharmaceuticals
Mandy Zhu
Associate Director
Crystal Pharmatech
Schedule a meeting with our experts.
When: March 23-26, 2026
Where: The Benjamin Royal Sonesta New York (125 E 50th St, New York, NY 10022)
Find Us: Suite 2001
_.webp "A Significant Step Toward Greater Clarity in Polymorph Control for Innovative Drugs")
Subscribe to be the first to get the updates!
